tance plays a major role in the pathogenesis of type 2 diabetes.
Many clinical practices suggest that the long-term use of Chinese medicinal herbs may be advantageous over chemical antidiabetes agents now used in alleviating some chronic symptoms and complications caused by diabetes, while adverse effects of these herbal extracts are minimal [6] . The isoquinoline alkaloid drug berberine ( Fig. 1) , one of the main bioactive herbal constituents of Rhizoma coptidis, has a wide range of pharmacological and biochemical effects. Berberine has been known to be used as antiinflammatory agent, antimicrobial agent, antihypertension agent, antiarrhythmias agent, antitumor agent [7] and antidiabetes agent [8, 9] . Although more recent studies have demonstrated the gene expression alterations associated with antidiabetic action of berberine [10, 11] , the gene expression alterations involved in therapeutic mechanisms of berberine on insulin resis-scribed [12] [13] [14] with slight modifications. Briefly, a majority of hamsters of both sexes were fed with high-fat diet containing 20% lard, 10% egg yolk powder, 1% cholesterol and 0.1% cholic acid (Institute of Laboratory Animal Science, CAMS & PUMC, Beijing, China) for 4 weeks. Then the diabetic hamsters were induced by injecting intraperitioneally twice with streptozotocin (Sigma-Aldrich, St. Louis, MO) 40 mg/kg body weight. The remaining hamsters of both sexes fed with standard laboratory chow were injected intraperitioneally with an equivalent volume of vehicle (0.05 M citric acid, pH 4.5). After treatment, the hamsters were kept on the same diet. Diabetic animals were determined by fasting blood glucose levels (≥ 9 mM) and oral glucose tolerance tests. After induction of animal models, the hamsters were randomly divided into three groups: control group, type 2 diabetic group and berberine-treated type 2 diabetic group (10 hamsters for the each group). According to our previous studies, in the berberine-treated type 2 diabetic group, the diabetic hamsters were treated orally with 150 mg/kg daily of berberine (berberine hydrochloride, B3251, Sigma-Aldrich, St. Louis, MO) in a carboxymethylcellulose (C4888, SigmaAldrich, St. Louis, MO) /PBS (1.5g/100 mL) formulation for a nine-week period. The hamsters in the control and type 2 diabetic groups were treated orally with an equivalent volume of vehicle (carboxymethylcellulose /PBS). All animals were still maintained in a controlled environment with a 12-h dark/light cycle and had free access to food and water throughout the study. After nine-week treatment, animals in the different groups were euthanized after a 12 h fasting period. Blood samples were obtained by retro-orbital sinus puncture under anesthesia with aether. The serum was separated by centrifugation at 3000 ×g for 20 min at 4 °C and stored at -80°C until the use for detertance of type 2 diabetes, especially hepatic insulin resistance are not fully understood.
For the present work, hamsters share genetic susceptibility for diabetes and many characteristic features of human lipid metabolism. Thus, we have developed a type 2 diabetic hamster model by highfat diet with streptozotocin injection according to the method previously published [12] [13] [14] . Our previous studies show that these type 2 diabetic hamsters closely simulate the natural history, metabolic characteristics and clinical symptoms of obese type 2 diabetes. Thus, the role of fat-induced insulin resistance in the pathogenesis of obese type 2 diabetes is well represented in these animal models. Subsequently, after nine-week treatment, berberine significantly reduces fasting blood glucose and lipid levels and improves fat-induced insulin resistance in our diabetic hamsters, exhibiting same therapeutic effect as metformin and mild pharmacological action. In addition, Microarray technology is a powerful tool to decipher the complex gene expression profiles altered by diseases with complex nature and drugs treatment. Therefore, in the present study, we use microarray technology to determine the hepatic gene expression alterations and explore the possible molecular mechanisms involved in therapeutic effect of berberine on fat-induced hepatic insulin resistance (FIHIR) in type 2 diabetic hamsters induced by high-fat diet with streptozotocin injection. An understanding of the molecular basis for berberine's therapeutic effect on FIHIR is helpful to improve therapeutic approaches to type 2 diabetes and related disorders.
Materials and Methods

Animals, induction of diabetes, group and berberine treatment
The five-month-old Golden Syrian hamsters of either sex were free of all known hamster pathogens and purchased from SiChuan Academy of Medical Sciences, SiChuan, China and were maintained under specific-pathogen-free husbandry conditions. Hamsters were housed individually in a temperature-(18-25°C) and humidity-(40-70%) controlled room with a 12/12 dark/light cycle with water and standard laboratory chow (1010 series of pellet feed, Institute of Laboratory Animal Science, CAMS & PUMC, Beijing, China) available to adapt to the environment for 2 weeks. Diabetes was induced as previously de- formaldehyde-agarose gel electrophoresis. 5 μg of total RNA was reversely transcribed into cDNA using cDNA Synthesis Kit (Promega, Madison, WI). After purification, cRNA was synthesized from the cDNA using T7 RiboMAX Express Large Scale RNA Production System (Promega, Madison, WI). 2 μg of cRNA was reversely transcribed into cDNA. 2 μg of cRNA reverse-transcribed products was labeled with either 40 μM dCTP-Cy5 or 40 μM dCTP-Cy3 (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA), KLENOW (Takara, Dalian, China), 9 Random Primer, 60 μM dCTP, and 120 μM dATP, dGTP, dTTP in a final volume of 200 μL, and the labeled cDNA was purified using PCR NucleoSpin Extract II Kit (Macherey-Nagel GmbH & Co. KG, Düren, Germany) and dried.
36k Mouse Genome (Mouse Genome Version 4.0 of Operon Co.) representing approximately 25,000 genes (for information, see http://www.operon.com), which share highly genetic homologous features of hamster, were printed in arrays on 75×25 mm slides with the use of SmartArray TM (CapitalBio Corp., Beijing, China). The labeled cDNA (0.9 μg) was added to a total of 30 μL hybridization solution containing 3× sodium chloride sodium citrate (SSC), 5× Denhart's, 25% formamide, and 0.2% sodium dodecyl sulphate (SDS). The labeled cDNA in hybridization solution was added to the microarray slide, and then hybridized to microarray at 42°C for 12 h. After hybridization the slides were washed at 42°C for 5 min in solution containing 2× SSC and 0.2% SDS, and then transferred to 0.2× SSC at room temperature for 5 min. Slides were dried by centrifugation. The liver tissues from three hamsters of each group were randomly selected to be used for microarray analysis. All experiments were performed in duplicate. Fluorescence intensities of microarray spots were measured using a laser doublechannel LuxScan 10KA scanner (CapitalBio Corp., Beijing, China). Image analysis was performed using GenePix Pro 4.0 software (Axon Instruments, Inc., Foster City, CA, USA). Then Lowess normalization was applied to the primary data. After the normalization, the ratio value was calculated. Furthermore, the differentially expressed genes (> 1.5-or < 1.5-fold) were determined. Then analysis of Gene Ontology was performed based on expressed differently genes.
Real Time RT-PCR
For verification of the microarray analysis results, real-time RT-PCR analysis of selected genes was permining metabolic and biochemical parameters. Livers were rapidly isolated 2.5 h after berberine or vehicle administration, weighed, and rapidly frozen in liquid nitrogen. The liver tissues were stored at -80°C until analysis. All procedures involving animal handling and tissue harvesting had been reviewed and approved by Institute of Laboratory Animal Science, CAMS & PUMC Laboratory Animal Care and Use Committee and Institutional Animal Welfare Committee.
Oral glucose tolerance tests
Oral glucose tolerance tests were performed after an overnight fast. Oral glucose load was administered at 2 g/kg. Blood samples were obtained under anesthesia with aether from the retro-orbital sinus at 0, 30, 60, 120 and 180 min after glucose challenge and blood glucose and insulin levels were measured.
Blood chemistries
Serum concentrations of free fatty acids (FFAs), total cholesterol (TC), low density lipoprotein (LDL)-C, high density lipoprotein (HDL)-C and triglycerides (TG) were analyzed using commercial kits (Randox Laboratories Ltd, Antrim, UK) in accordance with the manufacturer's instructions in a Hitachi 8060 automatic biochemical analyzer (Hitachi Co.Ltd, Tokyo, Japan). TC and TG were determined by Trinder-based (CHOD-PAP method and GPO-PAP method) colorimetric end-point assays using Randox total cholesterol kits (Cat.No.CH200) and triglycerides kits (Cat. No.TR1697). FFAs were measured by means of NEFA colorimetric method using Randox NEFA kits (Cat.No.FA115). HDL-C and LDL-C were quantified by a direct clearance method using Randox direct HDL-C kits (Cat.No.CH2652) and direct LDL-C kits (Cat.No.CH2656). Blood glucose was measured with an OneTouch® Ultra TM Blood Glucose Monitoring System (LifeScan International Inc., Milpitas, CA, USA). Serum insulin levels were determined using the Linco rat/mouse insulin enzyme-linked immunosorbent assay kit in accordance with the manufacturer's protocol (Linco Research, St. Charles, Missouri, USA).
Microarray analysis
Frozen liver tissues from the different groups were collected to extract total RNA with an RNeasy Mini Kit (Qiagen, Hilden, Germany). After purification, the quantity and quality of total RNA were determined by spectrophotometry. The RNA quality was checked by periment, compared with control group, the body weight and liver weight significantly increased in diabetic group. Besides decreased HDL-C, the serum lipid levels including FFAs, TC, LDL-C and TG were significantly increased in diabetic group. The blood glucose was significantly higher in diabetic group than that in control group. A relative hyperinsulinemia was observed in diabetic group. Compared with control group, blood glucose concentrations at different indicated time points of oral glucose tolerance test (OGTT) were higher ( Fig. 2A) , serum insulin levels during the OGTT were abnormal (Fig. 2B) , areas under the glucose curve ( Fig. 2C ) and insulin curve (Fig.  2D ) during the OGTT were larger, index of insulin resistance was higher (Table 2) in diabetic group. After berberine treatment, the body weight was decreased. But no significant difference was measured in body weight between diabetic and berberine-treated diabetic groups. Liver weight was significantly decreased in berberine-treated diabetic group compared with diabetic group. Compared with diabetic group, the serum lipid levels including FFAs, TC, LDL-C and TG and the blood glucose concentrations were significantly decreased in berberine-treated diabetic group. The serum insulin levels in berberine-treated diabetic group were similar with these in control group after berberine treatment. Compared with diabetic group, blood glucose concentrations at different indicated time points of OGTT ( Fig. 2A) were lower, areas under the glucose curve during the OGTT (Fig. 2C) were smaller, index of insulin resistance (Table 2 ) was lower in the berberine-treated diabetic group. The serum insulin levels during the OGTT (Fig. 2B) were restored after berberine treatment and no significant difference was measured in areas under the insulin curve during the OGTT between diabetic and berberinetreated diabetic groups (Fig. 2D) . Compared with diabetic group, berberine did not significantly reduce food intake (Fig. 3 ).
The alterations of hepatic gene expression in diabetic and berberine-treated diabetic hamsters
The results of the microarray analysis indicated that about 12.5% (3113) and 13.1% (3281) of the assessed genes showed significant changes (up-regulated or down-regulated 1.5-fold) in their mRNA levels in diabetic and berberine-treated diabetic hamsters, respectively. The number of differentially expressed genes was more in berberine-treated diabetic group than that formed using the SYBR Green method. Total RNA was extract from frozen liver tissues from the different groups with an RNeasy Mini kit (Qiagen, Hilden, Germany). The quantity and quality of total RNA were determined by spectrophotometry, and its integrity was assessed by 1% agarose gel electrophoresis. cDNA was synthesized from 1 μg of total RNA using a iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Inc., CA, USA) in accordance with the manufacturer's protocol. Specific primers pairs for each gene were designed using PRIMER EXPRESS software (Applied Biosystems, Foster City, CA, USA) or obtained from previously published papers. Then reverse-transcribed products of 50 ng total RNA were amplified with iQ Syber Green Supermix (Bio-Rad Laboratories, Inc., CA, USA) according to the manufacturer's protocol and carried out using iCycler iQ Real Time PCR Detection System (Bio-Rad Laboratories, Inc., CA, USA). Amplification conditions were: 95°C for 3 min, followed by 45 cycles of 95°C for 10 s and 59°C for 45 s. At the end of amplification, the reaction was further subjected to 80 cycles of 0.5°C increments (10 s each) beginning at 59°C for analysis of melting curve to check the identity and purity of the amplified products. Each reaction was performed in triplicate. To ensure specific amplification, negative controls were included in the PCR reaction. Real-time PCR efficiency measured before amplification was close to 1. Thus the relative quantification for a target gene in a given sample was calculated according to the 2(-Delta Delta C (T)) method [15] . β-actin was used as the reference gene. The nucleotide sequences of the forward and reverse primers were presented in Table 1 .
Statistical analysis
Data were expressed as mean ± SD. Statistical difference was assessed using the two-tailed student's t test and one-way analysis of variance (ANOVA). Statistical significance was displayed as P < 0.05. Analyses were performed using SPSS 13.0 for Windows software (Chicago, IL, USA).
Results
Metabolic characterization of diabetic and berberinetreated diabetic hamsters
The phenotypic and metabolic characterizations of diabetic and berberine-treated diabetic hamsters were measured and presented in Table 2 . At the end of ex-diabetes were mainly involved in hepatic lipid metabolism, glucose metabolism, hormonally regulated signaling pathways and some transcription/nuclear factors in diabetic and berberine-treated diabetic groups. Among the 256 and 271 genes, a total approximately 178 differentially expressed genes including 90 upregulated (> 1.5-fold) and 88 downregulated (< 1.5-fold) genes in both diabetic and berberine-treated diabetic groups was partially shown in Table 3 . However, the other differentially expressed genes were also up-regin diabetic group.
In diabetic group, approximate 1773 (7.1%) genes were upregulated and 1340 (5.4%) genes were downregulated among 3113 differentially expressed genes. While in berberine-treated diabetic group, about 1692 (6.8%) genes expression increased and 1589 (6.4%) genes expression decreased among 3281 differentially expressed genes. The results of Gene Ontology analysis indicated about 256 and 271 differentially expressed metabolism related genes associated with Fig. 3 Tendency of the changes in food intake from the different groups after berberine (BBR) treatment. Data were presented as mean ± SD (n = 10).
Fig. 2
Oral glucose tolerance tests (OGTT) in diabetic and berberine-treated diabetic hamsters. Diabetic hamsters were induced by high-fat feeding and streptozotocin injection. Then diabetic hamsters in diabetic or berberine-treated diabetic groups were treated orally with vehicle (carboxymethylcellulose/PBS (1.5g/100 mL)) and berberine (150 mg/kg) for 9 weeks, and OGTT were performed in control (diamonds), diabetic (squares) or berberine-treated diabetic groups (Triangles). Serum glucose (A) and insulin (B) concentrations at the indicated time points after glucose challenge were measured and values for areas under the glucose curve (C) and insulin curve (D) during OGTT were calculated for each hamster and averaged. Data were presented as mean ± S.D, n = 10 for the each group. *, P < 0.05 versus control group. #, P < 0.05 comparing diabetic group and berberinetreated diabetic group. 
Confirmation of the alterations of hepatic SREBPs, LXRα and PPARα transcriptional programs by realtime RT-PCR in diabetic and berberine-treated diabetic hamsters
In order to confirm the gene expression alterations involved in SREBPs, LXRα and PPARα transcriptional programs in the diabetic and berberine-treated diabetic hamsters, twenty-one key genes including LXRs, SREBPs and PPARα were chosen for further investigation by quantitative real-time RT-PCR analysis. Compared with control group, a significant increase in the SREBPs (SREBP-1a, SREBP-1c and SREBP-2) mRNA levels and a significant decrease in the LXRα and PPARα mRNA levels were observed in diabetic group. And that a significant increase in the LXRα, PPARα and SREBPs (SREBP-1a, SREBP-1c and SREBP-2) mRNA levels was seen in berberinetreated diabetic group. There was no change in the mRNA levels of LXRβ in both diabetic and berberinetreated diabetic groups. The expression of PEPCK, G-6-Pase, FAS, ACC, SCD-1, LDLR, HMG CoA synthase, HMG CoA reductase and PGC-1α was also significantly increased, while the expression of CYP7A1, Gck, Acox, Cpt1, Acadm and Acaa2 was significantly decreased in diabetic group. The expression of FAS, ACC, SCD-1, LDLR, HMG CoA synthase, HMG CoA reductase, CYP7A1, Gck, Acox, Cpt1, Acadm and Acaa2 was significantly increased, and the expression of PEPCK, G-6-Pase and PGC-1α was significantly decreased in berberine-treated diabetic group. Compared with diabetic group, the expression of SREBPs and their target genes including FAS, ACC, SCD-1, HMG CoA synthase and HMG CoA reductase significantly decreased, and that the expression of LXRα and PPARα and their target genes including CYP7A1, Gck, Acox, Cpt1 and Acadm significantly increased, as well as LDLR, in the berberine-treated diabetic group. At the same time the expression of gluconeogenic gene PEPCK, G-6-Pase and PGC-1α ulated in only diabetic group (36 genes) or berberinetreated diabetic group (43 genes) and down-regulated in only diabetic group (42 genes) or berberine-treated diabetic group (50 genes) (data not shown).
The alterations of hepatic SREBPs, LXRα and PPARα transcriptional programs in diabetic and berberinetreated diabetic hamsters Table 3 showed the expressions of SREBPs (SREBP-1, SREBP-2) genes were upregulated in diabetic group vs. control group. The expression of target genes of SREBP-1c implicated in fatty acid synthesis such as fatty acid synthase (FAS), acetyl-Coenzyme A carboxylase (ACC) and stearoyl-CoA desaturase-1 (SCD-1) was increased, and the expression of target genes of SREBP-2 involved in cholesterol metabolism including 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) synthase, HMG CoA reductase and low density lipoprotein receptor (LDLR) was also upregulated in diabetic group. In addition, the expression of phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G-6-Pase) and peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) regulated by LXRα was also increased in diabetic group vs. control group. A significant down-regulation was observed in LXRα and PPARα mRNA levels in diabetic group. The expression of target genes of PPARα such as acyl-CoA oxidase (Acox), carnitine-palmitoyl transferase 1 (Cpt1) and medium-chain acyl-CoA dehydrogenase (Acadm) was down-regulated, and the expression of genes regulated by LXRα including cholesterol 7alpha-hydroxylase (CYP7A1) and Glucokinase (Gck) was decreased in diabetic group vs. control group.
After berberine treatment, compared with control group, the increased gene expression of LXRα and PPARα was observed in berberine-treated diabetic group. The gene expression of Gck, CYP7A1, acetylCoenzyme A acyltransferase 2 (Acaa2), Acox, Cpt1 and Acadm was increased in berberine-treated diabetic group. The expressions of SREBPs (SREBP-1, SREBP-2) genes were upregulated and the expression of FAS, ACC, SCD-1, HMG CoA synthase, HMG CoA reductase and LDLR increased in berberine-treated diabetic group. But the expression of gluconeogenic gene PEPCK, G-6-Pase and PGC-1α was downregulated in berberine-treated diabetic group. Compared with diabetic group, the expression of SREBPs genes and their target genes including FAS, ACC, SCD-1,
Discussion
Because of the important role of FIHIR in the pathogenesis of obese type 2 diabetes, therefore, one of the major therapeutic goals of obese type 2 diabetes is to improve insulin resistance and enhance insulin action. Antidiabetes agents that ameliorate insulin resistance, so-called insulin-sensitizing agents, have been developed including berberine. Subsequently, although recent studies have demonstrated molecular mechanisms associated with antidiabetic action of berberine [9-11, 16, 17] , as a insulin-sensitizing agent, gene expression alterations involved in its therapeuregulated by LXRα was downregulated after berberine treatment. Further, a significant difference in the levels of expression of SREBPs, LXRα and PPARα and their certain target genes was found between diabetic and berberine-treated diabetic groups (Fig. 4) . Not all results obtained by the micoarray hybridizations were confirmed by the real-time RT-PCR, thus in the present study only data verified by the real-time RT-PCR were considered suitable for interpretation. Thus, altered LXRα, SREBPs and PPARα transcriptional programs were observed in the liver of berberine-treated type 2 diabetic hamsters. genesis. At the same time the reduced glucokinase expression in diabetic hamster is possibly upregulated by the increased LXRα to promote hepatic glucose utilization. Unfortunately, the increased LXRα also may induce the expression and activation of SREBP1c and lipogenic genes [19, 20] , despite this, hepatic lipogenesis associated with the increased LXRα seems not necessarily affect beneficial effect of berberine on FIHIR. The improvement of FIHIR is also associated with that the increased LXRα upregulate the decreased CYP7A1 expression in diabetic hamster after berberine treatment. Enhanced hepatic CYP7A1 expression may effectively prevent the hepatic cholesterol accumulation by increasing hepatic bile acid synthesis. In conclusion, the berberine-induced alterations of hepatic LXRα transcriptional programs contribute to improve FIHIR, decrease the blood glucose and lipid levels and further prevent the progress of obesity-related diabetes.
In addition, LXRβ which expression does not significantly change in diabetic and berberine-treated diabetic hamsters seems not involved in the development and therapy of FIHIR of type 2 diabetes. Our results indicated that the expression of hepatic SREBPs and their target genes including FAS, ACC, SCD-1, LDLR, HMG CoA synthase and HMG CoA reductase was significantly increased in diabetic hamsters. And that compared with diabetic hamsters, the tic molecular mechanisms on insulin resistance, especially FIHIR of type 2 diabetes are not fully understood. In this study, although the results of the microarray, which was only used for rough screening, did not undergo statistical analysis, the results of Gene Ontology analysis of micoarray data provided some important altered metabolism related genes associated with diabetes for follow-up PCR confirmation to help to demonstrate the therapeutic molecular mechanisms of berberine on FIHIR of type 2 diabetes. Thus only verified data were considered suitable for interpretation. Our results implied that altered hepatic SREBPs, LXRα and PPARα transcriptional programs may be involved in therapeutic molecular mechanisms of berberine on FIHIR of type 2 diabetes (Fig. 5) .
In our study, the expression of hepatic LXRα, CYP7A1 and Gck significantly decreased but hepatic PEPCK, G-6-Pase and PGC-1α expression significantly increased in diabetic hamsters. However, reversed gene expression alterations were observed in berberine-treated diabetic hamsters. These gene expression alterations imply that the increased hepatic key gluconeogenic genes expression such as PEPCK, G-6-Pase and PGC-1α in diabetic hamster, which help to induce the development of insulin resistance and the onset of diabetes [18] , is possibly downregulated by the increased LXRα to reduce hepatic gluconeo- Recently, Kim WS et al. [28] have shown that berberine-induced improvement of hyperlipidemia and fatty liver by intraperitoneal administration in obese animals including db/db and ob/ob mice is mediated by activation of AMP-activated protein kinase (AMPK) through increasing the phosphorylation levels of AMPK in peripheral tissues, notably liver and muscle, accompanied by changes in gene expression programs involved in lipid metabolism. In this study, we used the non-genetic type 2 diabetic hamsters to investigate the beneficial effects of berberine on FIHIR. Oral administration of berberine, more easily accepted for patients, differed from that used by Kim WS et al. and exhibited similar beneficial antidiabetic effects as proposed by Kim WS et al. Compared with the findings from Kim WS et al., our results of Microarray did not show the alteration of AMPK gene expression, which was consistent with previous studies that berberine improved insulin resistance and hyperlipidemia by activating AMPK [10] . Additionally, our results revealed that the therapeutic effects of berberine on FIHIR associated with glucose and lipid metabolism and their regulated signaling pathways and some transcription/nuclear factors simultaneously. Thus, in this study, combined gene expression alterations of hepatic SREBPs, LXRα and PPARα transcriptional programs were determined and their regulatory mechanisms were explored. Gene expression alterations and biological effects of LXRα transcriptional programs involved in therapeutic effects of berberine on FIHIR of type 2 diabetic hamsters were first described. At the same time, our findings indicated that berberine reduced the expression of many lipogenic genes including ADD1/SREBP-1c, PPAR-γ (data not shown), ACC, SCD, and FAS, which were similar with Kim WS et al. But Kim WS et al. did not report whether there existed the difference in the hepaic SREBPs transcriptional programs gene expression between berberine-treated diabetic and control animals. Such comparation of SREBPs transcriptional programs provided us many directions of further investigation including determining the relationship between increased hepaic SREBPs transcriptional programs and elevated LDLR. Our results also displayed similar berberine-induced gene expression alterations involved in enhanced fatty acid β-oxidation (PPARα transcriptional programs) and energy expenditure (uncoupling protein 2) (data not shown) with Kim WS et al. Furthermore, our results can explain the findings expression of hepatic SREBPs transcriptional programs significantly decreased in berberine-treated diabetic hamsters. Such hepatic gene expression alterations suggest that the increased expression of hepatic SREBPs transcriptional programs associated with hepatic lipid accumulation and hepatic insulin resistance as previously reported [21, 22] in diabetic hamsters. While the reduced expression of hepatic SREBPs transcriptional programs in berberine-treated diabetic hamsters is involved in berberine's therapeutic effect on FIHIR. Thus, these berberine-induced hepatic SREBPs transcriptional programs alterations contribute to alleviate hepatic lipogenesis and lipid accumulation and ameliorate FIHIR. However, the results also indicated that compared with control hamsters, the expression of hepaic SREBPs transcriptional programs is still increased. Even now, the enhanced expression of lipogenic genes seems not to exacerbate FIHIR and affect the therapeutic effect of berberine on FIHIR. Thus, it is still need further investigation whether the increased expression of hepatic SREBPs transcriptional programs is necessary to further reduce the blood lipid levels or not. In addition, less is known about whether the increased hepatic lipogenic genes expression is transient or more persistent.
PPARα, predominantly expresses in the liver, drives the genes transcription involved in peroxisomal and mitochondrial oxidation of fatty acids [23] . The results indicated that the expression of hepatic PPARα and fatty acid oxidizing related genes, such as Acox, Cpt1, Acadm and Acaa2 was significantly decreased in diabetic hamsters and increased in berberine-treated diabetic hamsters. These hepatic gene expression alterations suggest that the decreased expression of hepatic PPARα transcriptional programs involve in hepatic lipid accumulation and hepatic insulin resistance as previously described [24] [25] [26] [27] in diabetic hamsters. And the increased expression of hepatic PPARα transcriptional programs is associated with berberine's therapeutic effect on FIHIR. Thus, the increased berberine-induced hepatic PPARα transcriptional programs expression helps to enhance hepatic fatty acid β-oxidation and decrease hepatic and serum triglyceride levels and improve FIHIR. In addition, enhanced hepatic fatty acid β-oxidation together with increased CYP7A1 perhaps can offset the lipogenic effect induced by increased SREBPs to reduce blood lipid levels. Decreased blood lipid levels also help to further improve FIHIR. transcriptional programs expression alterations, closely associated with molecular mechamisms that berberine improves FIHIR in type 2 diabetic hamsters. In addition, the multiple different therapeutic molecular mechanisms of berberine on FIHIR share common multiple effective target genes such as hepatic glucose output (gluconeogenesis), hepatic glucose utilization, lipid and cholesterol biosynthesis, bile acid biosynthesis, fatty acids oxidation and energy expenditure. Here, we first present that berberine possess the property of antilipotoxicity in the liver of obese-related type 2 diabetes associated with diet.
